investors-2019-new

Why invest in Aspen?

We have a proud heritage dating back more than 160 years and we are committed to sustaining life and promoting healthcare through increasing access to our high quality, affordable medicines and products in more than 150 countries. Our commercial pharmaceutical focus is in the Regional Brands, Anaesthetics, Thrombosis, High Potency & Cytotoxic categories.

With a market capitalisation of approximately R117,9 billion as at 30 June 2018, Aspen is the largest pharmaceutical company listed on the JSE Limited (share code: APN).

The Group operates 23* manufacturing facilities across 15* sites and holds international manufacturing approvals from some of the most stringent global regulatory agencies. Our manufacturing capabilities are scalable to demand and cover a wide variety of product-types including injectables, oral solid dose, liquids, semi-solids, steriles, biologicals and active pharmaceutical ingredients.

* Since the divestment of our Nutritionals Business to the Lactalis Group on 31 May 2019 as per the SENS announcements issued on 13 September 2018 and 3 June 2019.

QUICK FACTS

Market capitalisation


R117,9 billion*

*As at 30 June 2018

Manufacturing facilities


23#

# Since the divestment of our Nutritionals Business to the Lactalis Group

SITES ACROSS THE GROUP


13#

#Since the divestment of our Nutritionals Business to the Lactalis Group

NUMBER OF Continents


6

APPROXIMATE Employees


10 000

INVESTMENT PROPOSITION

Please click on a title below left for more information.
Strong market position

Strong market position

  • One of the largest pharmaceutical companies in the southern hemisphere
  • Substantial presence in major developing markets such as Latin America, Russia, Eastern Europe, sub-Saharan Africa and South East Asia
  • Accredited manufacturing facilities that are scalable to demand
  • Vertical integration advantages for the manufacture of certain of Aspen’s leading global brands
  • The leading pharmaceutical company in South Africa
  • One of the top five pharmaceutical companies in Australia
Diversified geographies and product offering
Proven track record
Leverages on local knowledge and expertise
Centralised Group activities facilitate synergies and mitigate pricing pressures
Positive growth drivers
Responsible corporate citizen
Other considerations